Pfizer Hungarian joint venture
Executive Summary
To market Pfizer pharmaceuticals announced June 6 with Biogal Pharmaceutical Works of Debrecen, Hungary. Pfizer will own 51% of the joint venture, Pfizer Biogal Kft., which will be based in Budapest. Pfizer already licenses Minipress (prazosin) and the antibiotic Cefobid to Biogal; the two firms have been associated for more than a decade, Pfizer noted.